CareFusion 303, Inc

In the matter of CareFusion 303, Inc, the applicant sought patent protection for a system designed to manage medication delivery, including alerts for priority medication delivery. The dispute centred on whether the invention met the criteria for patentability under section 45 of the relevant legislation, specifically whether it constituted a manner of manufacture. The case was heard and determined by Dr N. R. Madsen, the delegate of the Commissioner of Patents.

The primary legal issue before the court was whether the invention claimed by CareFusion 303, Inc was a manner of manufacture, thereby qualifying for patent protection. This involved an examination of the claims and the specification to determine whether the invention was more than a mere scheme or business method. The court also considered whether the claims could be amended to satisfy the statutory requirements.

The court concluded that the claimed invention, as it stood, was not a manner of manufacture. The analysis of the specification indicated that the invention was primarily a scheme for managing medication delivery through specific notifications. The court noted that while the exact nature of potential amendments was not clear, it would allow a three-month period for the applicant to propose amendments to the claims. This decision was in line with previous cases such as Rokt Pte Ltd, which emphasised the importance of careful construction of the specification and claims when determining the nature of the invention.

The final order granted a period of three months for the applicant to consider and propose amendments to the claims to potentially address the identified deficiencies. This period was intended to provide the applicant an opportunity to reframe the claims in a manner that might satisfy the criteria for a manner of manufacture.